Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel vs Sandostatin LAR in Carcinoid Syndrome
NCT00092287Phase 3Terminated
- Sponsor
- Ipsen
- Start
- Jul 2004
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lanreotide in Carcinoid Syndrome (CS) (2 arms), sponsored by Ipsen. Primary endpoint: Target symptom frequency (flushing or stool frequency). Started Jul 2004; status: terminated.
02
Drugs
lanreotide
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on NCT00092287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092287.